1. Home
  2. L vs UTHR Comparison

L vs UTHR Comparison

Compare L & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Loews Corporation

L

Loews Corporation

HOLD

Current Price

$108.13

Market Cap

22.8B

Sector

Finance

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$538.30

Market Cap

25.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
L
UTHR
Founded
1969
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.8B
25.1B
IPO Year
1998
1999

Fundamental Metrics

Financial Performance
Metric
L
UTHR
Price
$108.13
$538.30
Analyst Decision
Buy
Analyst Count
0
14
Target Price
N/A
$567.57
AVG Volume (30 Days)
832.9K
483.4K
Earning Date
05-04-2026
05-06-2026
Dividend Yield
0.22%
N/A
EPS Growth
24.34
13.07
EPS
1.63
5.82
Revenue
$18,454,000,000.00
$1,483,300,000.00
Revenue This Year
N/A
$6.39
Revenue Next Year
N/A
$14.18
P/E Ratio
$65.82
$92.20
Revenue Growth
5.39
2.38
52 Week Low
$88.76
$272.18
52 Week High
$114.90
$609.35

Technical Indicators

Market Signals
Indicator
L
UTHR
Relative Strength Index (RSI) 54.28 39.51
Support Level $107.84 $534.97
Resistance Level $108.75 $542.66
Average True Range (ATR) 1.76 12.24
MACD 0.25 -0.67
Stochastic Oscillator 81.89 20.84

Price Performance

Historical Comparison
L
UTHR

About L Loews Corporation

Loews Corp is a holding company along with its subsidiary engaged in commercial property and casualty insurance, transportation and storage of natural gas and natural gas liquids, operation of a chain of hotels, and also in the manufacture of rigid plastic packaging solutions. It has four reportable segments comprised of three individual consolidated operating subsidiaries, CNA Financial Corporation, Boardwalk Pipeline Partners, LP and Loews Hotels Holding Corporation; and the Corporate segment.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: